Table 2. BRCA mutations and BRCAness frequencies.
|
a. Frequency of BRCA mutations in all TNBCsa | |||
|---|---|---|---|
| Neoadjuvant (n=152) | Familial (n=134) | Adjuvant (n=91) | |
|
Mutation analysis | |||
| BRCA1 (%) | 27 (24) | 0 (0) | 9 |
| BRCA2 (%) | 2 (2) | 0 (0) | 4 |
| BRCA1 UV (%) | 2 (2) | 16 (22) | 0 |
| BRCA2 UV (%) | 1 (1) | 7 (9) | 0 |
| Wild type (%) | 80 (71) | 51 (69) | 0 |
| ND |
40 |
60 |
78 |
|
b. Frequency of BRCAness in all TNBCs without BRCA1/2 mutationsb | |||
| |
Neoadjuvant (n=123) |
Familial (n=134) |
Adjuvant (n=78) |
|
aCGH | |||
| BRCA1 like (%) | 70 (66) | 92 (69) | 53 (68) |
| Non-BRCA1 like (%) | 35 (34) | 42 (31) | 25 (32) |
| ND |
18 |
0 |
0 |
|
BRCA1 promoter methylation | |||
| Methylated (%) | 31 (29) | 47 (37) | 21 (27) |
| Unmethylated (%) | 75 (71) | 81 (63) | 56 (73) |
| ND | 17 | 6 | 1 |
Abbreviations: aCGH=array Comparative Genomic Hybridisation; ND=not determined; TNBC=triple-negative breast cancer; UV=unclassified variant.
a
Patients with unknown characteristics (ND) were not included in P-value calculations; therefore percentages for these groups were not depicted in the table.
b
For Adjuvant series, only samples with a positive mutation test result were known; therefore, we could not calculate percentages.